Dr Reddy’s Launches Trientine Hydrochloride Capsules In US

Hyderabad, Feb.7 (Maxim News): Dr Reddy’s Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market. Trientine works by removing copper from the blood. It is used to treat Wilson’s disease, a genetic metabolic defect that causes excess copper to build up in the body.

In a regulatory filing, Dr Reddy’s Laboratories announced the launch of Trientine Hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules approved by the US Food and Drug Administration (USFDA). “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, Chief Executive Officer and Head of Dr. Reddy’s North America Generics. “Our product can be stored at room temperature (20°C to 25°C or 68°F to 77°F) throughout the product shelf life of 24 months.”

The Syprine brand and generic products had U.S. sales of approximately $94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health. (Maxim News)